Cilostazol in patients with ischemic stroke

Bibliography

• US Department of Health and Human Services, Food and Drug Adminstration. NME drug and new biological approval in 1999. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NMEDrugandNewBiologicApprovals/ucm081686.htm [Last accessed 10 September 2010]
   Google Scholar
• Shinohara Y, Katayama Y, Uchiyama S, Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959-68
   PubMed Web of Science ®Google Scholar
• Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001;19:369-86
   PubMed Web of Science ®Google Scholar
• Honda F, Imai H, Ishikawa M, Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke 2006;37:223-8
   Google Scholar
• Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 2010;9:273-84
   PubMed Web of Science ®Google Scholar
• Fumio Gotoh HT, Hirai S, Terashi A, Cilostazol in stroke prevention. J Stroke Cerebrovasc Dis 2000;9:147-57
   Google Scholar
• Nakamura T, Uchiyama S, Yamazaki M, Iwata M. Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation. Thromb Res 2007;119:511-16
   Google Scholar
• Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005;6:3-11
   PubMed Web of Science ®Google Scholar
• Omi H, Okayama N, Shimizu M, Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res 2004;68:119-25
   PubMed Web of Science ®Google Scholar
• Kitamoto S, Egashira K. Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. J Atheroscler Thromb 2002;9:261-5
   Google Scholar
• Cojocaru IM, Cojocaru M, Iliescu I, Plasma myeloperoxidase levels in patients with acute ischemic stroke. Rom J Intern Med 2010;48:101-4
   PubMedGoogle Scholar
• Hong KW, Lee JH, Kima KY, Cilostazol: therapeutic potential against focal cerebral ischemic damage. Curr Pharm Des 2006;12:565-73
   PubMed Web of Science ®Google Scholar
• Nonaka Y, Koumura A, Hyakkoku K, Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone. J Pharmacol Exp Ther 2009;330:13-22
   Google Scholar
• Suzuki S, Masui Y, Ohnuki M, Induction of metallothionein synthesis by cilostazol in mice and in human cultured neuronal cell lines. Biol Pharm Bull 2007;30:791-4
   PubMed Web of Science ®Google Scholar
• Hiratsuka M, Hinai Y, Sasaki T, Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos 2007;35:1730-2
   PubMed Web of Science ®Google Scholar
• Yoo HD, Park SA, Cho HY, Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects. Clin Pharmacol Ther 2009;86:281-4
   PubMed Web of Science ®Google Scholar
• Lee SP, Suh JW, Park KW, Study design and rationale of 'Influence of cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: a multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials 2010;11:87
   Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Hass WK, Easton JD, Adams HP Jr., Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-7
   PubMed Web of Science ®Google Scholar
• Lee JH, Cha JK, Lee SJ, Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Eur J Neurol 2010;17:434-42
   PubMedGoogle Scholar
• Huang Y, Cheng Y, Wu J, Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008;7:494-9
   PubMed Web of Science ®Google Scholar
• Kwon SU, Cho YJ, Koo JS, Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36:782-6
   PubMed Web of Science ®Google Scholar
• Samsung Medical Center. The comparison of effects between increased dose of clopidogrel and addition of cilostazol (4C-DES). Clincaltrials.gov. 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00620646?term=clopidogrel+AND+cilostazol&rank=1 [Last accessed 10 September 2010]
   Google Scholar
• Translational Research Informatics Center, Hyogo, Japan. Cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS). 2009. Available from: http://www.strokecenter.org/trials/TrialDetail.aspx?tid=624 [Last accessed 10 September 2010]
   Google Scholar
• Korea Otsuka Pharmaceutical Co. Effect of cilostazol in the acute lacunar infarction based on pulsatility index of transcranial doppler (ECLIPse). 2009. Available from: http://www.strokecenter.org/trials/TrialDetail.aspx?tid=738 [Last accessed 10 September 2010]
   Google Scholar
• Yamasaki Y, Kim YS, Kawamori R. Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study). Cardiovasc Diabetol 2006;5:16
   PubMedGoogle Scholar
• Han Y, Li Y, Wang S, Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-9
   PubMed Web of Science ®Google Scholar
• Ge J, Han Y, Jiang H, RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. J Cardiovasc Pharmacol 2005;46:162-6
   PubMedGoogle Scholar
• Takigawa T, Matsumaru Y, Hayakawa M, Cilostazol reduces restenosis after carotid artery stenting. J Vasc Surg 2010;51:51-6
   Google Scholar